Navigation Links
Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians
Date:9/22/2009

g 2011; however, physicians must demonstrate a full year of meaningful use of a CCHIT-certified solution, such as Allscripts MyWay. Adoption thereafter will result in decreased funding. Link High Technologies is providing physicians with Hi-tech Stimulus Act funding information to help provide clarity about the criteria needed for funding as well as the funding timetable.

About Link High Technologies, Inc.
Since 1992, Link High Technologies has been providing reliable, affordable, no-nonsense technology solutions to a widely diversified client base in government, education, finance, title, healthcare, research and manufacturing. For more information about Link High Technologies, please visit http://www.linkhigh.com or call (973) 659-1350.

###

Read the full story at http://www.prweb.com/releases/linkhigh/allscripts/prweb2902734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australias Strategic Partnership
2. Vestara and MedClean Technologies Announce Co-Marketing Partnership to Expand Innovative Solution for Pharmaceutical Waste Management
3. EF Johnson Technologies, Inc. Receives Notice Regarding Minimum Bid Price Rule
4. Health Plans Reduce Administrative Expenses with HEALTHsuite(R) from RAM Technologies, Inc.
5. China Medical Technologies Announces US$30 Million Share Repurchase Program
6. Global Med Technologies, Inc.s CEO to Make Major New Product Announcement the Morning of the LDV Investor Conference and Will Demo the Product on Wednesday, September 23, 2009
7. Greenway Medical Technologies PrimeLeader Conference Brings in Record Number of Customers as Company Continues Fast-Paced Growth
8. Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth, Personal Emergency Response and Medical Monitoring Systems
9. Global Med Technologies(R), Inc. Announces Its First EdgeCell Cellular Therapy Software and EdgeLab/HLA Software Sale in North America
10. Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
11. HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians
Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians
Breaking Medicine News(10 mins):Health News:Blood Thinner Combos Risky for Heart Attack Patients 2Health News:Centegra Expands H1N1 Vaccines to General Public 2Health News:Centegra Expands H1N1 Vaccines to General Public 3Health News:Centegra Expands H1N1 Vaccines to General Public 4Health News:Do Charitable Gift Donations Make a Difference? 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 2Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 3Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 4Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 5Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 6
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2RecoverCare and MedaSTAT USA Complete Transaction 53601 1RecoverCare and MedaSTAT USA Complete Transaction 53601 2RecoverCare and MedaSTAT USA Complete Transaction 53601 3BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2